What Can You Expect?
With over 400 active radiopharmaceutical drugs currently in development and expanding into new disease indications, this year’s 7th Targeted Radiopharmaceuticals Summit Europe returns with a refreshed and comprehensive programme. It now features an additional dedicated track covering the latest industry developments and addressing the most pressing challenges.
The summit offers a focused agenda centred on industry-specific topics, all designed to accelerate regulatory approvals, clinical progress, and commercialisation. Key areas of focus include isotope supply, clinical study design, dosimetry, novel molecular design, and much more.
Leave With Actionable Takeaways
Whether you’re building an early-stage pipeline or preparing for late-stage scale-up, this is your opportunity to connect with others facing the same challenges, and to move your programme forward with greater speed and confidence.
Turn early clinical signals into strong preclinical and first-in-human strategies
Fine-tune trial design, dosimetry, and dosing for new and emerging targets
Navigate isotope access, manufacturing challenges, and regulatory complexity
Tackle cross-border supply and logistical hurdles unique to Europe
Divide & Conquer
This programme has been specifically designed to address the key challenges at each stage of development, including a newly released third track of content: introducing a brand-new stream of information, allowing you to attend any track from Preclinical & Discovery, Translational & Clinical, and CMC & Sourcing.
A snapshot of key sessions featured in each track across the 2025 programme:
Discovery & Preclinical Track
Elucidating Radiobiological Mechanisms of Cytotoxicity & Immune Modulation to Inform Selection of Optimal Radiopharmaceutical Targets
- Bala Attili, Director, Oncology Safety Sciences, AstraZeneca
Translational & Clinical Development Track
Engineering Targeted Radiopharmaceuticals: DEP Dendrimer Nanoparticles for Optimised Biodistribution & Efficacy
- Jeremy Paull, Chief Scientific & Regulatory Officer, Star Pharma
CMC & Sourcing Track
Strategies to Mitigate Isotope Supply Challenges for Actinium to Ensure Consistent Supply
- Shaemus Gleason, Executive Vice President, Clarity Pharmaceuticals
Explore the Full Event Guide
- 250+ Attendees from Biopharma
- 40+ World-Class Speakers
- 12+ C-Level Speakers
- 6 Pre-Conference Day Sessions
- 3 Dedicated Tracks of Content
Attending Companies Include
Explore the Agenda
Explore the latest industry breakthroughs and get exclusive insights into radiopharmaceutical innovations with our expanded three-track agenda, covering discovery, preclinical research, translational science, clinical progress, CMC, and supply chain strategies.
Partner With Us
Align yourself with other leading solution providers to ensure your brand remains central to key biopharma deals and decision-making.
Join Biopharma Experts
Join the most important conversations with like-minded professionals across all stages of drug development, and build critical connections during dedicated networking sessions designed to foster collaboration and harmonisation throughout the entire development journey.